Navigation Links
BioMS Medical Announces Third Quarter 2008 Results
Date:11/6/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 6 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the third quarter ended September 30, 2008. BioMS Medical, in partnership with Eli Lilly and Company (Lilly), is developing dirucotide (MBP8298), a drug for the treatment of MS undergoing pivotal trials in Canada, Europe and the U.S.

"The third quarter saw positive developments in the dirucotide development plan, with completion of the interim analysis resulting in a significant milestone payment from our partner Lilly," said Kevin Giese, President and CEO of BioMS Medical. "Dirucotide was also granted fast track designation by the U.S. FDA, another important achievement which could potentially accelerate the development and review process for this important MS drug."

Currently, BioMS is conducting three clinical trials and one open-label follow-on trial for dirucotide (MBP8298):

- MAESTRO-01: A randomized, double-blind pivotal phase II/III trial in

Canada and Europe evaluating dirucotide (MBP8298) for the treatment

of secondary progressive MS (SPMS). The study has completed full

recruitment of 611 patients at 47 trial sites in 9 countries. To

date, there have been nine positive safety reviews from the Data

Safety Monitoring Board (DSMB). Full analysis of this trial is

expected in the second half of 2009.

- MAESTRO-02: An open-label follow-on study to the MAESTRO-01 pivotal

trial. Eligible patients who have successfully completed the blinded,

placebo controlled MAESTRO-01 trial may choose to receive dirucotide

(MBP8298) on an un-blinded basis. To date, approximately 95% of

patients enrolled in MAESTRO-01 have proceeded to MAESTRO-02.

- MAESTRO-03: A U.S. pivotal phase III trial evaluatin
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... NORTH BRUNSWICK, New Jersey , ... Pharmaceuticals, société de découverte médicamenteuse spécialisée ... d,agents antibiotiques destinés à soigner les ... annoncé aujourd,hui la présentation de données ... clinique majeur, le TXA709, dans la ...
(Date:4/27/2015)... HEIDELBERG , Germany ... Addresses unmet need in treatment of millions of cancer ... been granted a patent in Europe ... supports Molecular Health,s discovery that EPHB4 is a novel receptor ... tumor growth. EPO stimulates the production of red blood cells ...
(Date:4/27/2015)... April 27, 2015  Together with its customers, Elekta ... Forum in Barcelona . The funds ... with the mission to improve cancer care, specifically radiation ... believes that no patient should be denied potentially life-saving ... it cooperates with hospitals and clinics around the world ...
(Date:4/24/2015)... April 24, 2015 Leading Regenerative ... in its allogeneic stem-cell product development program and ... reflect the corporate strategic direction. , “I am ... adipose stem cell development program has been kicked ... cGMP manufacturing facility and hiring of our new ...
Breaking Biology Technology:TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6Molecular Health Gains Patent for Novel Receptor Utilizing Computational Biomarker Discovery Technology 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 2Elekta helps raise $33,000 to bring radiation treatment to developing countries 3Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma 2
... to maneuver separately without any obvious guidance are now ... led by a Duke University computer scientist. , "It,s ... at this fine a resolution with such very, very ... computer science and biochemistry. , Each microrobot is shaped ...
... DIEGO, June 2 Amylin Pharmaceuticals,Inc. (Nasdaq: ... present new data,for its FDA-approved diabetes drugs, BYETTA(R) ... pipeline diabetes and,obesity drug candidates at the American ... in San Francisco, CA from June 6 to,10. ...
... , CALL DATE: Tuesday, June 3, 2008, ... HOST: Dr. Candace Kendle, Chairman ... telephone conference call and,simultaneous webcast on Tuesday, June 3 at 9:30 ... that,was announced on May 30 and to provide an update on ...
Cached Biology Technology:Microrobots dance on something smaller than a pin's head 2Microrobots dance on something smaller than a pin's head 3Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 2Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 3Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 4Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 5Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 6Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 7Kendle to Host Conference Call and Webcast to Discuss DecisionLine Acquisition and Provide Update on Second Quarter Progress 2
(Date:4/21/2015)... , April 21, 2015 ... government policies are boosting access control systems market in ... According to a recently published report by TechSci Research ... ", the access control systems market in ... billion by 2020.The access control systems market in the ...
(Date:4/20/2015)... April 20, 2015 The announcement ... Glenbeigh Records Management (GRM), Ireland,s ... Islamic Bank. Having built up an impressive track record of ... leading player within the records management sector in ... double is GCC staffbase and employ a further eight staff ...
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... different species manage to coexist. If two species ... will be more efficient and out-compete the other. ... evolved morphological or physiological traits that allow it ... other species. Such partitioning of resources essentially provides ...
... Great Barrier Reef released by the CSIRO shows for the ... travel to the outer reef, and beyond. , The ... year, challenge conventional thought that sediment travelling from our river ... and travels no more than 10 to 15km offshore, affecting ...
... chess, the reason may be in your genes. , ... University School of Medicine in St. Louis, has gathered the ... signaling pathways in the brain influences one kind of intelligence. ... performance IQ, which involves a person's ability to organize things ...
Cached Biology News:Virtual duck bills demonstrate species coexistence 2CSIRO imagery shows Outer Great Barrier Reef at risk from river plumes 2Genes and genius: Researchers confirm association between gene and intelligence 2Genes and genius: Researchers confirm association between gene and intelligence 3
The PROTEAN II xi multi-cell 2-D conversion kit converts the PROTEAN II xi multi-cell to the PROTEAN II XL multi-cell for a wider format cell that accepts 17 to 18 cm IPG strips....
4',6-Diamidino-2-phenylindole, dihydrochloride (DAPI)...
... This depletion cocktail is ... cells from suspensions of rat ... using the StemSep (or compatible ... system. The T cell content ...
CleanCut agarose is used to prepare genomic DNA plugs for use in pulsed field gel electrophoresis (PFGE) applications. Supplied as a 12 ml solution of 2% agarose....
Biology Products: